Opus Genetics (IRD) Liabilities and Shareholders Equity (2010 - 2026)

Opus Genetics (IRD) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $66.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 38.66% year-over-year to $66.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $191.8 million (up 12.67% YoY) and the FY2025 annual result came in at $50.2 million, up 36.3% from the prior year.
• Liabilities and Shareholders Equity grew to $66.8 million in Q1 2026 per IRD's latest filing, from $50.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $66.8 million in Q1 2026 and bottomed at $14.6 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $44.8 million (2024), against an average of $41.9 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity tumbled 37.22%; it then soared 271.99% in 2023.
• Tracing IRD's Liabilities and Shareholders Equity over 5 years: stood at $49.0 million in 2022, then gained by 10.12% to $53.9 million in 2023, then slumped by 31.67% to $36.9 million in 2024, then surged by 36.3% to $50.2 million in 2025, then jumped by 32.93% to $66.8 million in 2026.
• Per Business Quant, the three latest IRD Liabilities and Shareholders Equity figures stand at $66.8 million (Q1 2026), $50.2 million (Q4 2025), and $36.1 million (Q3 2025).

Peer Comparison